Ardelyx traded at $5.73 this Friday February 20th, decreasing $1.01 or 14.99 percent since the previous trading session. Looking back, over the last four weeks, Ardelyx lost 28.29 percent. Over the last 12 months, its price rose by 13.24 percent. Looking ahead, we forecast Ardelyx to be priced at 5.55 by the end of this quarter and at 5.05 in one year, according to Trading Economics global macro models projections and analysts expectations.
Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.